Stocks of Moderna Inc (NASDAQ:MRNA) traded higher last session on Wall Street, up 2.96% to $110.59.
MRNA stock price is now 11.87% away from the 50-day moving average and 9.99% away from the 200-day moving average. The market capitalization of the company currently stands at $42.34B.
With the price target enhanced from $75 to $86, HSBC Securities Downgraded its rating from Hold to Reduce for Moderna Inc (NASDAQ: MRNA). On January 02, 2024, Oppenheimer Upgraded its previous ‘Perform’ rating to ‘Outperform’ on the stock keeping its target price maintained at $142, while ‘Canaccord Genuity’ rates the stock as ‘Hold’
In other news, AFEYAN NOUBAR, Director sold 15,000 shares of the company’s stock on Mar 20 ’24. The stock was sold for $1,535,820 at an average price of $102.39. Upon completion of the transaction, the Director now directly owns 2,116,931 shares in the company, valued at $234.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 15 ’24, President Hoge Stephen sold 15,000 shares of the business’s stock. A total of $1,547,550 was realized by selling the stock at an average price of $103.17. This leaves the insider owning 1,501,241 shares of the company worth $166.02 million. A total of 12.19% of the company’s stock is owned by insiders.
During the past 12 months, Moderna Inc has had a low of $62.55 and a high of $163.24. As of last week, the company has a debt-to-equity ratio of 0.09, a current ratio of 3.42, and a quick ratio of 3.36. The fifty day moving average price for MRNA is $99.03 and a two-hundred day moving average price translates $100.48 for the stock.
The latest earnings results from Moderna Inc (NASDAQ: MRNA) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at $0.55, beating analysts’ expectations of -$0.97 by 1.52. This compares to $3.74 EPS in the same period last year. The net profit margin was -68.76% and return on equity was -28.59% for MRNA. The company reported revenue of $2.81 billion for the quarter, compared to $5.08 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -44.71 percent. For the current quarter, analysts expect MRNA to generate $277.15M in revenue.
